Skip to main content

Table 2 Most common AEs by treatment cycle in patients with best response of SD to romidepsin

From: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Drug related/non-drug related, n

Treatment cycle

Any (n = 32)

1 (n = 32)

2 (n = 28)

3 (n = 25)

4 (n = 21)

5 (n = 14)

6 (n = 11)

>6 (n = 5)

Any grade AEs reported in > 20 % of patients with best response of SD

 Nausea

22/2

18/2

6/0

5/0

5/1

5/0

0/0

1/0

 Asthenia/fatigue

19/1

13/0

6/0

4/0

4/0

3/1

2/1

1/0

 Infections SOC

6/11

4/6

1/3

1/2

0/5

1/1

1/2

1/2

 Dysgeusia

14/0

8/0

7/0

1/0

2/0

0/0

0/0

0/0

 Vomiting

12/1

5/0

4/1

4/0

3/1

4/0

0/0

1/0

 Diarrhea

7/5

5/1

4/2

1/0

1/0

0/1

0/1

1/0

 Constipation

5/6

3/3

0/0

2/0

0/0

1/1

0/0

0/1

 Anorexia

11/0

6/0

3/0

3/0

1/0

2/0

0/0

1/0

 Thrombocytopenia

10/0

6/0

2/0

3/0

2/0

2/0

2/0

0/0

 Pyrexia

7/1

1/1

1/0

0/1

2/1

1/1

1/1

1/1

 Neutropenia

7/0

4/0

4/0

3/0

2/0

1/0

1/0

2/0

 Anemia

6/1

1/1

2/0

1/0

1/0

0/0

1/0

2/0

Grade ≥ 3 AEs reported in > 1 patients with best response of SD

 Neutropenia

7/0

4/0

3/0

2/0

1/0

1/0

0/0

2/0

 Thrombocytopenia

6/0

3/0

1/0

1/0

1/0

1/0

1/0

0/0

 Infections SOC

2/3

1/2

0/0

0/0

0/0

0/0

1/0

0/2

 Anemia

3/0

0/0

1/0

0/0

0/0

0/0

1/0

1/0

  1. Patients who experienced drug-related events may have also experienced non-drug-related events
  2. SOC system organ class